Claims for Patent: 9,181,277

Summary for Patent: 9,181,277

Title:	Aminoquinazoline derivatives and their salts and methods of use
Abstract:	The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. Also provided herein are pharmaceutically acceptable compositions comprising the aminoquinazoline compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
Inventor(s):	Zhang; Jiancun (San Mateo, CA), Zhang; Yingjun (Dongguan, CN), Zhang; Weihong (Dongguan, CN), Liu; Bing (Dongguan, CN), Zhang; Jiquan (Dongguan, CN), Liu; Jinlei (Dongguan, CN), Zhang; Lu (Dongguan, CN)
Assignee:	SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN)
Application Number:	14/346,741
Patent Claims:	1. A compound having formula (III) ##STR00297## wherein each of X.sup.9, X.sup.10 and X.sup.11 is independently CR.sup.eR.sup.f, NR.sup.e, O or S, with the proviso that at least one of X.sup.9, X.sup.10 and X.sup.11 is CR.sup.eR.sup.f; D is a bond, methylene or ethylene; each of R.sup.e and R.sup.f is independently H, C.sub.1-6 alkyl, C.sub.1-6 alkylacyl, C.sub.3-8 cycloalkyl, C.sub.6-10 aryl-C.sub.1-6-alkyl, or C.sub.1-6 haloalkyl; and n is 1 or 2. 2. A compound having one of the following structures: ##STR00298## ##STR00299## ##STR00300## ##STR00301## ##STR00302## ##STR00303## ##STR00304## ##STR00305## ##STR00306## ##STR00307## ##STR00308## ##STR00309## ##STR00310## ##STR00311## ##STR00312## ##STR00313## ##STR00314## ##STR00315## ##STR00316## or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, or a pharmaceutically acceptable salt thereof. 3. A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle or a combination thereof. 4. The pharmaceutical composition according to claim 3 further comprising a therapeutic agent selected from a chemotherapeutic agent, an anti-proliferative agent, an agent for treating non-small cell lung cancer or epidermoid carcinoma, or a combination thereof. 5. The pharmaceutical composition according to claim 4, wherein the therapeutic agent is adriamycin, rapamycin, temsirolimus, everolimus, ixabepilone, gemcitabine, cyclophosphamide, dexamethasone, etoposide, fluorouracil, imatinibmesylate, dasatinib, nilotinib, erlotinib, lapatinib, gefitinib, sorafenib, sunitinib, an interferon, carboplatin, topotecan, taxol, vinblastine, vincristine, temozolomide, tositumomab, trabectedin, bevacizumab, trastuzumab, cetuximab, panitumumab or a combination thereof. 6. A pharmaceutical composition comprising the compound according to claim 2 and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle or a combination thereof. 7. The pharmaceutical composition according to claim 6 further comprising a therapeutic agent selected from a chemotherapeutic agent, an anti-proliferative agent, an agent for treating non-small cell lung cancer or epidermoid carcinoma, or a combination thereof. 8. The pharmaceutical composition according to claim 7, wherein the therapeutic agent is adriamycin, rapamycin, temsirolimus, everolimus, ixabepilone, gemcitabine, cyclophosphamide, dexamethasone, etoposide, fluorouracil, imatinibmesylate, dasatinib, nilotinib, erlotinib, lapatinib, gefitinib, sorafenib, sunitinib, an interferon, carboplatin, topotecan, taxol, vinblastine, vincristine, temozolomide, tositumomab, trabectedin, bevacizumab, trastuzumab, cetuximab, panitumumab or a combination thereof.

Details for Patent 9,181,277

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2031-11-14
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2031-11-14
Glaxosmithkline Llc	BEXXAR	tositumomab and iodine i-131 tositumomab	Injection	125011	06/27/2003		2031-11-14
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2031-11-14